Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Veracyte, Inc (VCYT) PT Raised to $23 at BTIG
February 26, 2019 8:49 AM ESTBTIG analyst Sung Ji Nam raised the price target on Veracyte, Inc (NASDAQ: VCYT) to $23.00 (from $17.00) while maintaining a Buy rating, citing continued strong momentum for product portfolio.
The analyst commented, "VCYT capped off 2018 on a strong note with full year revenue growth of +28% (vs. initial guidance of +13-15%) and cash burn of $15.4mm, +39% improvement y/y (vs. initial guidance of $18-22mm, +20% improvement at... More
Veracyte (VCYT) Tops Q4 EPS by 7c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
February 25, 2019 4:19 PM ESTVeracyte (NASDAQ: VCYT) reported Q4 EPS of ($0.08), $0.07 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $24.36 million.
We delivered exceptional growth in 2018 and are off to a strong start in 2019, said Bonnie Anderson, Veracytes chairman and chief executive officer. Our 2018 performance was driven by several factors. Our Afirma GSC and Xpression Atlas launch broadened our thyroid offering to inform both diagnosis and treatment decisions,... More
